https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51503 Wed 28 Feb 2024 14:50:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45172 Wed 26 Oct 2022 14:18:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32190 Wed 09 Mar 2022 16:01:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24323 T (n=18) and MC_T/CPA3 (mRNA expression of TPSAB1 and CPA3; n=29) subtypes were identified, as well as a group without mast cell gene expression (n=8). The MC_T/CPA3 subtype had elevated exhaled nitric oxide fraction, sputum eosinophils, bronchial sensitivity and reactivity, and poorer asthma control. This was accompanied by upregulation of 13 genes. Multivariable logistic regression identified CPA3 (OR 1.21, p=0.004) rather than TPSAB1 (OR 0.92, p=0.502) as a determinant of eosinophilic asthma. The MC_T/CPA3 subtype had a better clinical response and reduced signature gene expression with corticosteroid treatment. Sputum mast cell subtypes of asthma can be defined by a molecular phenotyping approach. The MC_T/CPA3 subtype demonstrated increased bronchial sensitivity and reactivity, and signature gene expression, which was associated with airway eosinophilia and greater corticosteroid responsiveness.]]> Wed 09 Mar 2022 15:59:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49079 Wed 03 May 2023 16:14:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21583 Tue 26 Jun 2018 11:28:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44917 P <0.001). In conclusion, the consumption of fast foods, particularly hamburgers, correlates to asthma in a dose-response pattern, which needs to be further validated in longitudinal and interventional studies.]]> Tue 25 Oct 2022 09:17:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16898 Tue 23 Jul 2019 12:22:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46337 P = .01), emergency visit (RR = 8.61, P = .03), and hospitalization (RR = 12.94, P < .01). Results of the cluster analysis were successfully validated in an independent PGA population classified using decision tree analysis. Although PGA can transform into or develop from other phenotypes, 70% were stable over time. Conclusions: Among 3 identified PGA clusters, cluster 3 had a higher risk of severe exacerbation. PGA heterogeneity indicates the requirement of novel targeted interventions.]]> Tue 15 Nov 2022 15:03:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52770 Tue 14 Nov 2023 15:04:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43085 Tue 13 Sep 2022 12:19:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51598 Tue 12 Sep 2023 12:25:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38811 Tue 08 Feb 2022 14:30:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51880 Thu 21 Sep 2023 10:25:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54912 Thu 21 Mar 2024 12:03:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43316 Thu 15 Sep 2022 14:15:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32186 Thu 13 Jan 2022 10:28:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48870 Thu 13 Apr 2023 12:48:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49346 Thu 11 May 2023 16:31:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50719 Thu 03 Aug 2023 09:12:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46500 low) and high VFA (VFA^high) groups. Relationships between VFA and clinical and inflammatory features of asthma were analyzed by using correlation analysis. Univariate and multivariable negative binomial regression analyses were performed to investigate the association of VFA with exacerbations within a 12-month follow-up period. Results: The patients in the VFA^high group were older and had a longer asthma duration. Interleukin (IL) 6 and IL-8 in sputum were higher, whereas fractional exhaled nitric oxide (FeNO) and blood eosinophils were lower in the VFA^high group. Gender-differentiated correlations of VFA with clinical and inflammatory variables were observed in age, FeNO, immunoglobulin E, blood total white cells and neutrophils, and sputum IL-1β and IL-8. Furthermore, compared with the VFA^low group, the VFA^high group was at significantly increased risk of moderate-to-severe exacerbations (adjusted incidence rate ratio [IRR] 1.55 [95% confidence interval {CI}, 1.06‐2.28; p = 0.025), severe exacerbations (adjusted IRR 2.25 [95% CI, 1.26‐4.04]; p = 0.007), and emergency visits (adjusted IRR 5.33 [95% CI, 1.78‐17.16]; p = 0.003). Conclusion: The level of VFA was associated with specific clinical and inflammatory characteristics of asthma. Furthermore, VFA, as an independent risk factor, was associated with an increased risk of exacerbations. It indicated that VFA would provide more potential clinical implications for asthma management.]]> Thu 01 Dec 2022 15:34:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13350 Sat 24 Mar 2018 08:17:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13648 Sat 24 Mar 2018 08:17:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13647 Sat 24 Mar 2018 08:17:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20919 Sat 24 Mar 2018 08:06:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18992 Sat 24 Mar 2018 08:05:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26115 12 years with a chronic cough of > 8 weeks' duration that was unexplained after systematic investigation and treatment were included and assessed for relevance and quality. Based on the systematic review, guideline suggestions were developed and voted on by using the American College of Chest Physicians organization methodology. Results: Eleven RCTs and five systematic reviews were included. The 11 RCTs reported data on 570 participants with chronic cough who received a variety of interventions. Study quality was high in 10 RCTs. The studies used an assortment of descriptors and assessments to identify UCC. Although gabapentin and morphine exhibited positive effects on cough-related quality of life, only gabapentin was supported as a treatment recommendation. Studies of inhaled corticosteroids (ICS) were affected by intervention fidelity bias; when this factor was addressed, ICS were found to be ineffective for UCC. Esomeprazole was ineffective for UCC without features of gastroesophageal acid reflux. Studies addressing nonacid gastroesophageal reflux disease were not identified. A multimodality speech pathology intervention improved cough severity. Conclusions: The evidence supporting the diagnosis and management of UCC is limited. UCC requires further study to establish agreed terminology and the optimal methods of investigation using established criteria for intervention fidelity. Speech pathology-based cough suppression is suggested as a treatment option for UCC. This guideline presents suggestions for diagnosis and treatment based on the best available evidence and identifies gaps in our knowledge as well as areas for future research.]]> Sat 24 Mar 2018 07:41:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29176 Sat 24 Mar 2018 07:35:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23529 Sat 24 Mar 2018 07:13:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54966 Mon 25 Mar 2024 12:11:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47551 Mon 23 Jan 2023 12:29:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52682 Fri 20 Oct 2023 09:44:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53110 2-agonist. This study shows that, in response to the limitation of a stepwise approach to therapy, treatable traits is a new strategy where patients are individually assessed for a specified set of treatable problems, and an individualized treatment program is developed and implemented based on this multidimensional assessment, especially for difficult-to-treat asthma.]]> Fri 17 Nov 2023 11:25:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37034 Fri 14 Aug 2020 13:03:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47306 Fri 13 Jan 2023 10:52:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46081 adj], 18.10 and 19.17, respectively) and mechanical ventilation (RR_adj , 2.56 and 5.71, respectively) than did cluster 1. Individuals in cluster 3 had an extended length of hospital stay (11 days), increased hospitalization direct costs (13,481.57 Chinese Yuan), and a higher risk of ICU admission (RR_adj , 2.14) than individuals in clusters 1 and 2. The decision tree assigned 90.8% of the participants correctly. Conclusions: We identified 3 phenotypes with differential clinical and inflammatory characteristics associated with in-hospital adverse outcomes. These new phenotypes might have important and clinically relevant implications for the management of patients hospitalized for AEs.]]> Fri 11 Nov 2022 15:15:03 AEDT ]]>